Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)

Company Overview - The company has transitioned from a small biotech firm to a more established organization, launching its first product during the pandemic [3] - The leadership team has undergone significant changes, focusing on enhancing the company's structure and strategy post-Sanofi deal [2][3] Leadership and Team - The current leadership team includes John Jacobs as President and CEO, Jim Kelly as CFO, and Ruxandra Draghia-Akli as EVP and Head of R&D, who recently joined the company [1][2] - The team emphasizes the credentials and expertise of its members, highlighting their qualifications and contributions to the company [2] Strategic Focus - The company's strategy post-Sanofi has been to leverage its technology platform to drive growth and innovation [3] - There is a strong emphasis on adapting the expense profile and operational structure to align with the new strategic direction [3]